Xue Hou

5.2k total citations · 1 hit paper
104 papers, 2.1k citations indexed

About

Xue Hou is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Xue Hou has authored 104 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 61 papers in Pulmonary and Respiratory Medicine and 13 papers in Surgery. Recurrent topics in Xue Hou's work include Lung Cancer Treatments and Mutations (48 papers), Lung Cancer Research Studies (34 papers) and Lung Cancer Diagnosis and Treatment (21 papers). Xue Hou is often cited by papers focused on Lung Cancer Treatments and Mutations (48 papers), Lung Cancer Research Studies (34 papers) and Lung Cancer Diagnosis and Treatment (21 papers). Xue Hou collaborates with scholars based in China, United States and Hong Kong. Xue Hou's co-authors include Yan Huang, Hongyun Zhao, Yuanyuan Zhao, Yunpeng Yang, Wenfeng Fang, Yuxiang Ma, Ting Zhou, Li Zhang, Likun Chen and Shaodong Hong and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Xue Hou

97 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

2018 326 citations Wenfeng Fang, Yunpeng Yang et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Xue Hou

Since Specialization

Citations

This map shows the geographic impact of Xue Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xue Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xue Hou more than expected).

Fields of papers citing papers by Xue Hou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xue Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xue Hou. The network helps show where Xue Hou may publish in the future.

Co-authorship network of co-authors of Xue Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Xue Hou. A scholar is included among the top collaborators of Xue Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xue Hou. Xue Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastases 2025 ·npj Precision Oncology ·Jing Chen, (unknown), Meichen Li, Hui Yu, (unknown), (unknown), Xue Hou, Likun Chen	0
2	Temporal trends in the burden of tracheal, bronchial, and lung cancer in China and globally: A comprehensive analysis from 1990 to 2021 2025 ·PubMed ·(unknown), (unknown), Xue Hou, Qing Zhou	1
3	LBA3 First-line HLX07 vs. placebo combined with serplulimab and chemotherapy for nasopharyngeal cancer: A randomised, double-blind, multicentre phase II study 2024 ·Annals of Oncology ·(unknown), (unknown), (unknown), Lei Feng, (unknown), Haibo Ni, Xue Hou, (unknown), (unknown), (unknown)	1
4	Exploring Fatty Acid β-Oxidation Pathways in Bacteria: From General Mechanisms to DSF Signaling and Pathogenicity in Xanthomonas 2024 ·Current Microbiology ·Zhiyong Wang, Xue Hou, Guohui Shang, (unknown), Kai Luo, Mugen Peng	7
5	Effects of movement training based on rhythmic auditory stimulation in cognitive impairment: a meta-analysis of randomized controlled clinical trial 2024 ·Frontiers in Neuroscience ·Ya Nan Wang, (unknown), Yu Chen, Nuo Xu, Jing Zhang, Xue Hou, (unknown), Ping Li, (unknown), (unknown), (unknown)	7
6	329MO HLX208, a novel BRAF V600E inhibitor, in adult patients with Langerhans cell histiocytosis and/or Erdheim-Chester disease harbouring BRAF V600E mutation 2023 ·Annals of Oncology ·(unknown), Yi‐Long Wu, Pan Liu, Tao Ding, (unknown), (unknown), Yi Zhang, Junpeng Ma, Yu Xu, Gang Fu, Chen Hu, Xue Hou, Qīng Wáng, Jia Zhu, Jianping Li	1
7	1316MO BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study 2023 ·Annals of Oncology ·Li Zhang, Yuxiang Ma, Yuanyuan Zhao, Wenfeng Fang, Hongyun Zhao, Yan Huang, Yunpeng Yang, Xue Hou, (unknown), Shuang Zhang, Jing Wang, (unknown), H. Wang, Hai‐Dong Zhu, Martin Olivo, Yao Zhu	9
8	Near complete response to ceritinib in a pediatric patient with metastatic ALK-rearranged lung adenocarcinoma 2022 ·Lung Cancer ·(unknown), Maolin Liu, Xue Hou	1
9	Modification of Pathologic T Classification for Non-small Cell Lung Cancer With Visceral Pleural Invasion 2021 ·CHEST Journal ·(unknown), (unknown), Bob T. Li, Jietian Jin, Valerie W. Rusch, David R. Jones, Yi‐Long Wu, Qing Liu, Jie Yang, (unknown), Shuo Li, Hao Long, (unknown), Lanjun Zhang, Peng Lin, Tiehua Rong, Xue Hou, Suxia Lin, Hao‐Xian Yang	14
10	HPV-16 E2/E6 and POU5F1B as Biomarkers to Determine Cervical High-Grade Squamous Lesions and More 2020 ·SHILAP Revista de lepidopterología ·(unknown), Baijun Dong, H. Gao, Xue Hou, Di Pan, Peng Sun	1
11	P1.11-09 Risk of Second Primary Malignancy After Non-Small-Cell Lung Cancer: A Competing Risk Nomogram Based on the SEER Database 2019 ·Journal of Thoracic Oncology ·Huaqiang Zhou, Jiayi Shen, Yu Zhang, Yan Huang, Wenfeng Fang, Yunpeng Yang, Shaodong Hong, (unknown), Shen Zhao, (unknown), Zhiyuan Zhang, Jun Liu, Wei Xian, Yuanyuan Zhao, Xue Hou, Yuxiang Ma, Ting Zhou, Hongyun Zhao, Li Zhang	1
12	Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis 2018 ·Journal for ImmunoTherapy of Cancer ·Yixin Zhou, Chen Chen, Xuanye Zhang, Sha Fu, Cong Xue, Yuxiang Ma, Wenfeng Fang, Yunpeng Yang, Xue Hou, Yan Huang, Hongyun Zhao, Shaodong Hong, Li Zhang	82
13	Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma 2018 ·Drug Design Development and Therapy ·Yuanyuan Zhao, Ying Tian, Lin Liu, (unknown), Xue Hou, Xi Chen, Ting Zhou, Yan Huang, Li Zhang	12
14	Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials breakdown → 2018 ·The Lancet Oncology ·Wenfeng Fang, Yunpeng Yang, Yuxiang Ma, Shaodong Hong, Lizhu Lin, Xiaohui He, Jianping Xiong, Ping Li, Hongyun Zhao, Yan Huang, Yang Zhang, Likun Chen, Ningning Zhou, Yuanyuan Zhao, Xue Hou, Qing Yang, Li Zhang	326
15	Low uric acid is a risk factor in mild cognitive impairment 2017 ·SHILAP Revista de lepidopterología ·Xue Li, Liu Y, Xue Hou, Jin Xue, Sun H. Kim, (unknown), Ping Hou	2
16	Vascular Endothelial Growth Factor is a Useful Predictor of Postoperative Distant Metastasis and Survival Prognosis in Esophageal Squamous Cell Carcinoma 2015 ·Annals of Surgical Oncology ·Xue Hou, Jin-Chang Wei, Jianhua Fu, Xin Wang, Rong-Zhen Luo, Jie‐Hua He, Lan-Jun Zhang, Peng Lin, Hao‐Xian Yang	10
17	An investigation of symptom burden and quality of life in Chinese chemo-naïve advanced lung cancer patients by using the Instrument-Cloud QOL System 2014 ·Lung Cancer ·Yuxiang Ma, Yunpeng Yang, Yan Huang, Hongyun Zhao, Xue Hou, Ying Tian, Yuanyuan Zhao, Cong Xue, Wenfeng Fang, Xuan Wu, Zhihuang Hu, Wenhua Liang, Ting Zhou, Tao Qin, Li Zhang	10
18	The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients 2014 ·Tumor Biology ·Shaodong Hong, Ting Zhou, Wenfeng Fang, Cong Xue, Zhihuang Hu, Tao Qin, Yanna Tang, Yue Chen, Yuxiang Ma, Yunpeng Yang, Xue Hou, Yan Huang, Hongyun Zhao, Yuanyuan Zhao, Li Zhang	104
19	Survival and Risk Factors of Surgically Treated Mediastinal Invasion T4 Non-Small Cell Lung Cancer 2009 ·The Annals of Thoracic Surgery ·Hao‐Xian Yang, Xue Hou, Peng Lin, Tie-Hua Rong, Hong Yang, Jianhua Fu	36
20	Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease 2009 ·Journal of Thoracic Oncology ·Hao‐Xian Yang, Xue Hou, Peng Lin, Hong Yang, (unknown), Tie-Hua Rong, (unknown)	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact